Dissolution of intraocular fibrinous exudate by streptokinase.
In a prospective, open, pilot study, the authors evaluated the effects of intraocular injection of streptokinase on intraocular fibrin. The study was composed of nine patients in whom fibrinous exudate developed after pars plana vitrectomy. There were seven male and two female patients with a mean age of 44 years (range, 27 to 65 years). Fibrinous exudates were seen 1 to 22 days after surgery with obstruction of the view of the posterior segment. Each patient received a single intraocular injection of 1000 IU of purified streptokinase. Four hours after the streptokinase injection, complete dissolution of the fibrin was noted in each patient. There were no clinically detectable adverse effects from the intraocular administration of streptokinase. Streptokinase may be considered in the dissolution of intractable intraocular fibrinous exudates after vitrectomy.
Cherfan
G M
GM
Department of Ophthalmology, El Maghraby Eye Hospital, Jeddah, Saudi Arabia.
el Maghraby
A
A
Tabbara
K F
KF
Nasr
Y
Y
Hassan
H
H
D000328:Adult; D000368:Aged; D002387:Cataract Extraction; D002452:Cell Count / Q000187:drug effects; D004728:Endothelium, Corneal / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005337:Fibrin / Q000378:metabolism*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D013300:Streptokinase / Q000008:administration & dosage*; D014821:Vitrectomy / Q000009:adverse effects; D014822:Vitreous Body / Q000378:metabolism*
D005337:Fibrin; D013300:Streptokinase